Receptors Somatostatin
Mostrando 1-12 de 93 artigos, teses e dissertações.
-
1. ANÁLISE DA EXPRESSÃO DOS RECEPTORES DA SOMATOSTATINA (SST1-5) E DA DOPAMINA (DR2) EM ADENOMAS HIPOFISÁRIOS / ANALYSIS OF EXPRESSION OF THE RECEPTORS OF THE SOMATOSTATIN (SST1-5) AND DOPAMINE (DR2) IN PITUITARY ADENOMAS
Pituitary tumors represent 15% of intracranial neoplasms and are usually benign. The treatment primary is surgical resection with exception for prolactinomas because dopamine agonists are very effective in the treatment these tumors. If surgery does not lead to healing, it is necessary other therapeutic strategy in a attempt to control hormone levels and tum
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 12/03/2012
-
2. Effect of the administration of octreotide, cabergoline and the association of both on ACTH and cortisol levels in patients with Cushings disease: correlation of clinical response with tumoral expression of the dopamine (DRD2) and somatostatin (SSTR2 and SSTR5) receptors / Efeito da administração de octreotide, cabergolina e a associação de ambos nos níveis de ACTH e cortisol em pacientes com doença de Cushing: correlação da resposta clínica com a expressão tumoral dos receptores de dopamina (DRD2) e de somatostatina (SSTR2 e SSTR5)
Introdução: A doença de Cushing apresenta elevada morbimortalidade. Seu tratamento de escolha é a cirurgia transesfenoidal que possui resultados satisfatórios em cerca de 70% dos casos. Na doença persistente ou recorrente, reabordagem cirúrgica, radioterapia e adrenalectomia bilateral podem ser realizadas, porém, essas opções apresentam como desvan
Publicado em: 2010
-
3. Somatostatin analogs in acromegaly: comparison of clinic response, laboratory and tumor volume with expression of somatostatin receptor subtype in somatotroph tumor / Análogos da somatostatina na acromegalia: comparação da resposta clínica, laboratorial e do volume tumoral com a expressão dos subtipos dos receptores de somatostatina no tumor somatotrófico
Este estudo analisa a expressão dos subtipos de receptores da somatostatina (SSTR) em 39 adenomas secretores de GH. Em 19 pacientes acromegálicos, a resposta clínica, laboratorial e radiológica ao análogo da somatostatina (AS) octreotide-LAR foi comparada à expressão dos SSTR. O SSTR mais freqüentemente expresso foi o SSTR5, seguido pelos SSTR3, SSTR
Publicado em: 2008
-
4. PREPARATION OF LYOPHILIZED KIT OF HYNIC-[Tyr3]-OCTREOTATE AND LABELING STUDIES WITH 99m-TECHNETIUM / Preparo do reagente liofilizado HYNIC-[Tyr3]-Octreotato e estudo de marcação com Tecnécio-99m
The development of radiolabeled molecules with high specificity for an organ or tumor has been contributed to the precise diagnostic in nuclear medicine. Somatostatin labeled derivatives constitutes a particular example of labeled peptide applied in the localization of neuroendocrine tumors. Nowadays, the 111In-DTPA-octreotideo is the radiopharmaceutical app
Publicado em: 2008
-
5. Expression of somatostatin receptor type 2 (SSTR-2) and its relation with lymphatic metastasis and preoperative clinical features in typical bronchopulmonary carcinoid tumors / Expressão de receptores de somatostatina subtipo 2 (SSTR-2) e a sua relação com metástase linfática e variáveis clínicas pré-operatórias em tumores carcinóides broncopulmonares típicos
Os tumores carcinóides broncopulmonares típicos (CT) são proliferações de células neuroendócrinas. Foram consideradas como adenomas e acreditava-se que não tinham potencial para disseminação hematogênica e linfática. Porém, a ocorrência de metástase linfática e hematogênica acontece em um quinto dos indivíduos acometidos por essa patologia.
Publicado em: 2008
-
6. Somatostatin receptors are expressed by immature cerebellar granule cells: evidence for a direct inhibitory effect of somatostatin on neuroblast activity.
Somatostatin and somatostatin receptors are transiently expressed in the immature rat cerebellar cortex but virtually undetectable in the cerebellum of adults. Although somatostatin binding sites have been visualized during the postnatal period in the external granule cell layer, the type of cell that expresses somatostatin receptors has never been identifie
-
7. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney.
Somatostatin is a tetradecapeptide that is widely distributed in the body. It acts on multiple organs including brain, pituitary, gut, exocrine and endocrine pancreas, adrenals, thyroid, and kidneys to inhibit release of many hormones and other secretory proteins. In addition, it functions as a neuropeptide affecting the electrical activity of neurons. Somat
-
8. Cloning and characterization of a fourth human somatostatin receptor.
We have isolated a gene coding for a fourth human somatostatin (somatotropin release-inhibiting factor) receptor. This additional somatostatin receptor (hSSTR4) is specifically expressed in human fetal and adult brain and lung tissue. The deduced amino acid sequence of the receptor displays both sequence and structural homology to three cloned somatostatin r
-
9. Somatostatin content and receptors in the cerebral cortex of depressed and control subjects.
Somatostatin-like immunoreactivity is reduced in the cerebrospinal fluid in depression and this is presumed to reflect alterations in cerebral somatostatinergic systems. We have examined this hypothesis by measuring this immunoreactivity and somatostatin receptors in post-mortem cortical tissue from depressed patients and control subjects. There was no signi
-
10. Expression of peptide receptors in human endocrine tumours of the pancreas.
BACKGROUND: Gut peptides are known to influence hormone release and growth of endocrine tumours of the pancreas. Although information on somatostatin receptors has been provided recently, little is known on the receptor status of other gastrointestinal hormones in such tumours. AIMS: To analyse the spectrum of gut hormone receptors on endocrine tumours of pa
-
11. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
Membrane receptors for luteinizing hormone-releasing hormone (LH-RH), somatostatin, and prolactin (PRL) were investigated in the Dunning R-3327H rat prostate adenocarcinoma specimens after in vivo treatment with microcapsules of the agonist [D-Trp6]LH-RH and the somatostatin analog RC-160. The LH-RH receptors showed a low-binding affinity (Kd = 54 nM) and hi
-
12. Somatostatin receptors: identification and characterization in rat brain membranes.
We have identified and characterized specific receptors for tetradecapeptide somatostatin (SRIF; somatotropin release-inhibiting factor) in rat brain using [125I]Tyr11]SRIF as the radioligand. These receptors are present in membranes obtained from a subfraction of synaptosomes. Membranes derived from cerebral cortex bind SRIF with high affinity (Ka = 1.25 X